2026 Global: Drug-Eluting Stent (Des) Market -Competitive Review (2032) report
Description
The 2026 Global: Drug-Eluting Stent (Des) Market-Competitive Review (2032) report features the global market size and projected growth/decline data for the period 2021 and 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Leading players in the drug-eluting stent (DES) market include Abbott Vascular (Abbott Park, United States), Boston Scientific (Marlborough, United States), Medtronic (Dublin, Ireland), and Cordis (New Brunswick, United States). Abbott's Xience line popularized everolimus-eluting stents and remains central to many revascularization programs, offering polymer coatings, deliverability, and applicability. Boston Scientific's DES portfolio—anchored by Taxus and Promus platforms—has evolved toward improved polymer control, reduced complexity, and visibility during implantation. Medtronic's Resolute line uses sirolimus with precise polymer control to limit restenosis while preserving endothelial healing, supported by imaging and trial data. Cordis, as part of Johnson & Johnson, contributed early Cypher sirolimus-eluting technology shaped regulatory expectations and long-term outcome tracking. Collectively, these firms define benchmarks in biocompatibility, mechanical design, and surveillance, sustaining a competitive landscape that drives ongoing innovation across materials science, stent architecture, and procedural technique. Headquarters: Abbott Park, United States; Marlborough, United States; Dublin, Ireland; New Brunswick, United States.
Biotronik, headquartered in Berlin, Germany, expands DES options with stent platforms engineered for polymer control, radiopacity, and thin struts that facilitate deliverability in complex lesions. Its Orsiro drug-eluting stent exemplifies the integration of pharmacology with a durable coating aimed at reducing restenosis and late events. Biosensors International, headquartered in Singapore, Singapore, contributes the BioMatrix line and related platforms, emphasizing biocompatible polymers and clinical performance across diverse populations. Terumo, headquartered in Tokyo, Japan, advances the Ultimaster family with a tacrolimus-eluting design that supports rapid endothelialization and favorable long-term safety margins. Lepu Medical Technology, headquartered in Beijing, China, has expanded its DES offerings through partnerships and in-house R&D to address markets in Asia and beyond. Together these firms broaden the DES ecosystem by combining polymer science, stent geometry, and production scale across multiple regulatory jurisdictions. They operate across Europe, the Americas, and East Asia, collaborating with clinicians to optimize outcomes globally worldwide.
MicroPort Medical, headquartered in Shanghai, China, addresses regional demand with a range of DES variants that emphasize manufacturability, cost efficiency, and rapid market entry. Nipro Corporation, headquartered in Osaka, Japan, offers both drug-eluting designs and comprehensive quality systems that align with Japan's stringent safety standards. Together with the other eight players, MicroPort and Nipro contribute to a diversified DES landscape characterized by regional specialization, scale manufacturing, and cross-border distribution. Their presence reinforces the global nature of DES development, from early biocompatibility trials to large cardiovascular outcomes studies. In this environment, competition among Abbott, Boston Scientific, Medtronic, Cordis, Biotronik, Biosensors International, Terumo, Lepu Medical, MicroPort, and Nipro drives ongoing improvements in polymer science, stent geometry, and procedural techniques, while regulators push for clearer postmarket surveillance and standardized outcome reporting. The result is a dynamic ecosystem where innovation translates into safer devices, faster implantation, and better long-term outcomes for patients worldwide today.
Leading players in the drug-eluting stent (DES) market include Abbott Vascular (Abbott Park, United States), Boston Scientific (Marlborough, United States), Medtronic (Dublin, Ireland), and Cordis (New Brunswick, United States). Abbott's Xience line popularized everolimus-eluting stents and remains central to many revascularization programs, offering polymer coatings, deliverability, and applicability. Boston Scientific's DES portfolio—anchored by Taxus and Promus platforms—has evolved toward improved polymer control, reduced complexity, and visibility during implantation. Medtronic's Resolute line uses sirolimus with precise polymer control to limit restenosis while preserving endothelial healing, supported by imaging and trial data. Cordis, as part of Johnson & Johnson, contributed early Cypher sirolimus-eluting technology shaped regulatory expectations and long-term outcome tracking. Collectively, these firms define benchmarks in biocompatibility, mechanical design, and surveillance, sustaining a competitive landscape that drives ongoing innovation across materials science, stent architecture, and procedural technique. Headquarters: Abbott Park, United States; Marlborough, United States; Dublin, Ireland; New Brunswick, United States.
Biotronik, headquartered in Berlin, Germany, expands DES options with stent platforms engineered for polymer control, radiopacity, and thin struts that facilitate deliverability in complex lesions. Its Orsiro drug-eluting stent exemplifies the integration of pharmacology with a durable coating aimed at reducing restenosis and late events. Biosensors International, headquartered in Singapore, Singapore, contributes the BioMatrix line and related platforms, emphasizing biocompatible polymers and clinical performance across diverse populations. Terumo, headquartered in Tokyo, Japan, advances the Ultimaster family with a tacrolimus-eluting design that supports rapid endothelialization and favorable long-term safety margins. Lepu Medical Technology, headquartered in Beijing, China, has expanded its DES offerings through partnerships and in-house R&D to address markets in Asia and beyond. Together these firms broaden the DES ecosystem by combining polymer science, stent geometry, and production scale across multiple regulatory jurisdictions. They operate across Europe, the Americas, and East Asia, collaborating with clinicians to optimize outcomes globally worldwide.
MicroPort Medical, headquartered in Shanghai, China, addresses regional demand with a range of DES variants that emphasize manufacturability, cost efficiency, and rapid market entry. Nipro Corporation, headquartered in Osaka, Japan, offers both drug-eluting designs and comprehensive quality systems that align with Japan's stringent safety standards. Together with the other eight players, MicroPort and Nipro contribute to a diversified DES landscape characterized by regional specialization, scale manufacturing, and cross-border distribution. Their presence reinforces the global nature of DES development, from early biocompatibility trials to large cardiovascular outcomes studies. In this environment, competition among Abbott, Boston Scientific, Medtronic, Cordis, Biotronik, Biosensors International, Terumo, Lepu Medical, MicroPort, and Nipro drives ongoing improvements in polymer science, stent geometry, and procedural techniques, while regulators push for clearer postmarket surveillance and standardized outcome reporting. The result is a dynamic ecosystem where innovation translates into safer devices, faster implantation, and better long-term outcomes for patients worldwide today.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
